Immunome's Antibody Cocktail Neutralizes SARS-CoV-2 Delta Variant In Pre-clinical Testing; Stock Up

Immunome Inc. (IMNM) said that its three-antibody cocktail (IMM-BCP-01) has neutralized the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.

In Tuesday pre-market trading, IMNM was trading at $21.03 up $4.39 or 26.38%.

In addition, the antibody cocktail showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.

The company plans to explore opportunities to expedite the development of this potential therapeutic.

The company also plans to submit an IND application with the U.S. Food and Drug Administration this quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT